Subgroup Identification in Alzheimer's Disease Trial

Abstract

Background: Alzheimer's disease (AD) and its precursor, mild cognitive impairment (MCI), present significant challenges due to heterogeneous progression and treatment responses. Identifying subgroups of patients who benefit from specific treatments, such as Donepezil, is critical for advancing precision medicine in AD management.

The paper